Drug intelligence / Profile preview

GLPG0974

Development stage: Phase 2
Lead developer: Galapagos
Modality: Small Molecules
Administration: Oral

Overview

GLPG0974 is an orally available small molecule antagonist of the free fatty acid receptor 2 (FFA2, also known as GPR43), a G protein-coupled receptor activated by short-chain fatty acids produced from dietary fiber fermentation in the gut. FFA2 plays a key role in neutrophil activation and migration, contributing to inflammatory processes such as those seen in ulcerative colitis. By selectively inhibiting FFA2, GLPG0974 reduces neutrophil migration and activation, offering a novel anti-inflammatory mechanism for potential treatment of inflammatory bowel diseases. The drug was developed by Galapagos and has undergone Phase 1 and Phase 2 clinical trials for ulcerative colitis[1][2][6][7][8].

Other names: 1391076-61-1X7REK61AISX-7REK61AISX 7REK61AIS

Targets

FFAR2

Beyond the preview

Go deeper on GLPG0974.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLPG0974.

Explore the full profile